Related Experiment Video
Updated: Jun 10, 2026
Biochemical Measurement of Neonatal Hypoxia
Published on: August 24, 2011
Potential biomarkers for hypoxic-ischemic encephalopathy
1Fetal Physiology and Neuroscience Group, Department of Physiology, University of Auckland, Private Bag 92019, Auckland, New Zealand. l.bennet@auckland.ac.nz
Insights
Developing accurate biomarkers is crucial for identifying infants who can benefit from therapeutic hypothermia after birth-related hypoxia-ischemia (HI). Current biomarkers are often imprecise and lack utility during the critical treatment window.
Area of Science:
- Neonatal neurology
- Biomarker research
- Hypoxia-ischemia injury
Background:
- Therapeutic hypothermia improves outcomes for infants with hypoxia-ischemia (HI).
- Current enrollment criteria for hypothermia treatment are suboptimal, leading to undertreatment and overtreatment.
- Improved biomarkers are needed to precisely identify infants who can benefit from intervention.
Purpose of the Study:
- To critically evaluate the utility of proposed biomarkers for neonatal brain injury after HI.
- To assess biomarkers against the 'window of opportunity' for effective treatment (up to 6-8 hours post-HI).
- To identify limitations of current biomarkers in identifying treatable injury and predicting long-term outcomes.
Main Methods:
- Review of experimental studies on biochemical, electronic monitoring, and imaging biomarkers.
- Evaluation of biomarker precision and timing relative to the latent phase of HI injury.
- Analysis of biomarker correlation with injury severity and long-term neurodevelopmental outcomes.
Main Results:
- Most current biomarkers are most precise for severe injuries, which are already easily identified.
- Biomarker correlation is strongest after the critical 'latent phase' when injury is no longer treatable.
- Existing biomarkers have limited utility in identifying infants who can benefit from early intervention.
Conclusions:
- There is a critical need for novel biomarkers that are precise during the treatable 'latent phase' of HI.
- Accurate biomarkers are essential for optimizing therapeutic hypothermia enrollment and improving clinical trial design.
- Further research is required to develop biomarkers that can accurately predict neurodevelopmental outcomes and guide treatment decisions in neonates with HI.
Abstract:
Cerebral hypothermia reduces brain injury and improves behavioral recovery after hypoxia-ischemia (HI) at birth. However, using current enrolment criteria many infants are not helped, and conversely, a significant proportion of control infants survive without disability. In order to further improve treatment we need better biomarkers of injury. A 'true' biomarker for the phase of evolving, 'treatable' injury would allow us to identify not only whether infants are at risk of damage, but also whether they are still able to benefit from intervention. Even a less specific measure that allowed either more precise early identification of infants at risk of adverse neurodevelopmental outcome would reduce the variance of outcome of trials, improving trial power while reducing the number of infants unnecessarily treated. Finally, valid short-term surrogates for long term outcome after treatment would allow more rapid completion of preliminary evaluation and thus allow new strategies to be tested more rapidly. Experimental studies have demonstrated that there is a relatively limited 'window of opportunity' for effective treatment (up to about 6-8h after HI, the 'latent phase'), before secondary cell death begins. We critically evaluate the utility of proposed biochemical, electronic monitoring, and imaging biomarkers against this framework. This review highlights the two central limitations of most presently available biomarkers: that they are most precise for infants with severe injury who are already easily identified, and that their correlation is strongest at times well after the latent phase, when injury is no longer 'treatable'. This is an important area for further research.
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:23Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...